← Back to Discover
Versant Venture Management, LLC
Period ended Jun 30, 2026 · Latest filing Aug 12, 2026
These quarterly holdings are delayed and may not include all assets or short positions.
Values are from the reporting date, not current prices or purchase costs.
The same security may appear in multiple rows.
Source: SEC
Reported portfolio value
Quarter-end reported holdings; not current value or investment performance.
View reported values
- Jun 30, 2026: $162,612,689
More quarters will appear as history becomes available.
Top holdings
Top 10 at Jun 30, 2026. Matching entries are combined; security classes and options remain separate. Shares exclude principal amounts; option shares reflect the reported underlying amount.
View top holdings values
- Monte Rosa Therapeutics, Inc. · Common Stock · 61225M102 · shares: $76,974,876
- Century Therapeutics, Inc. · Common Stock · 15673T100 · shares: $29,806,967
- Jade Biosciences, Inc. · Common Stock · 008064206 · shares: $22,037,418
- Lenz Therapeutics, Inc. · Common Stock · 52635N103 · shares: $15,091,124
- Contineum Therapeutics, Inc. · Common Stock · 21217B100 · shares: $8,893,673
- CRISPR Therapeutics AG · Common Shares · H17182108 · shares: $8,117,243
- Skye Bioscience, Inc. · Common Stock · 83086J200 · shares: $1,391,941
- Tempest Therapeutics, Inc. · Common Stock · 87978U108 · shares: $299,447
Reported holdings
8 reported entries| Issuer | Class | CUSIP | Type | Shares / principal | Reported value (USD) |
|---|---|---|---|---|---|
| Monte Rosa Therapeutics, Inc. | Common Stock | 61225M102 | — | 3,180,780 shares | $76,974,876 |
| Century Therapeutics, Inc. | Common Stock | 15673T100 | — | 12,166,109 shares | $29,806,967 |
| Jade Biosciences, Inc. | Common Stock | 008064206 | — | 991,783 shares | $22,037,418 |
| Lenz Therapeutics, Inc. | Common Stock | 52635N103 | — | 2,656,888 shares | $15,091,124 |
| Contineum Therapeutics, Inc. | Common Stock | 21217B100 | — | 542,628 shares | $8,893,673 |
| CRISPR Therapeutics AG | Common Shares | H17182108 | — | 148,831 shares | $8,117,243 |
| Skye Bioscience, Inc. | Common Stock | 83086J200 | — | 2,007,704 shares | $1,391,941 |
| Tempest Therapeutics, Inc. | Common Stock | 87978U108 | — | 269,772 shares | $299,447 |